Aclaris 制药

最新新闻

• 评级变动
  LifeSci Capital Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/6/2
• H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Wedbush Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $8
  \u5e02\u573a\u8d44\u8baf · 2025/7/31
• 评级变动
  Wedbush Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $10
  \u5e02\u573a\u8d44\u8baf · 2026/4/29
• LifeSci Capital Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  Craig-Hallum Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/1/30
• 评级变动
  Guggenheim Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/5/5
• Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $11
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  Cantor Fitzgerald Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2025/10/15
• 评级变动
  Oppenheimer Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/4/16
• 评级变动
  Leerink Partners Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $7
  \u5e02\u573a\u8d44\u8baf · 2025/10/16
• 评级变动
  Guggenheim Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• 评级变动
  Wedbush Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/5/9
• 评级变动
  Wedbush Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $8
  \u5e02\u573a\u8d44\u8baf · 2026/1/14
• 评级变动
  Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $11
  \u5e02\u573a\u8d44\u8baf · 2026/5/5
• 评级变动
  H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Cuts Target Price to $16
  \u5e02\u573a\u8d44\u8baf · 2025/8/29
• 评级变动
  Oppenheimer Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $6
  \u5e02\u573a\u8d44\u8baf · 2025/10/15
• CCORF Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/9/1

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。